drugset / Trial / NCT00759928

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

NCT00759928 ↗

Phase 1 Completed 48 enrolled SCRI Development Innovations, LLC Bayer · collab
NaSingle-groupOpen-labelTreatment

Summary

Two cohorts of patients will be enrolled: Cohort A will consist of patients who are current smokers, and Cohort B will consist of patients who are current nonsmokers. There will be 24 patients enrolled in each cohort. Nonsmokers are patients who have not consumed tobacco or nicotine-containing products for 1 year before the start of the study. Patients classified as current smokers must have smoked a minimum of 10 cigarettes per day for up to 1 year. Patients who have smoked 1-9 cigarettes per day for up to 1 year, or more than 10 cigarettes per day for less than 1 year will not be eligible for this study.

Timeline

Start
2008-10
Primary completion
2013-09
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule 150 mg Oral
Subject Sorafenib Small molecule 400 mg Oral